Abstract:729 Background: This study conducted a large-scale multi-center analysis using real-world data from China to comprehensively investigate the clinical characteristics and prognosis of patients with deficient mismatch repair (dMMR) or high microsatellite instability (MSI-H) gastric and colorectal cancer undergoing curative surgery. Additionally, we analyzed postoperative adjuvant treatment effects and recurrence/metastasis patterns. Methods: We retrospectively analyzed 1800 gastric and colorectal cancer patients with dMMR and/or MSI-H confirmed by immunohistochemistry (IHC) and PCR after radical resection from 19 hospitals in China. We compared clinical characteristics among positive patients identified by both testing methods and evaluated their relationship with disease-free survival (DFS) and overall survival (OS). Results: The cohort included 1702 dMMR patients (regardless of MSI status), 667 MSI-H patients (regardless of MMR status), and 46 cases with inconsistent MMR and MSI statuses. No significant differences in overall clinical-pathological characteristics were observed between IHC-dMMR and PCR-MSI-H patients, highlighting the clinical utility of both approaches. Predominantly, MMR protein defects involved MLH1/PMS2 loss (>70%). We found a positive correlation between lymph node metastasis and MLH1/PMS2 protein deficiency (P<0.01) and an inverse correlation trend in cases of MSH2/MSH6 deficiency (P<0.1). Additionally, poorer prognosis was linked to alcohol consumption (DFS, P<0.001), lymph node metastasis (DFS, P<0.001; OS, P<0.001), vascular cancer emboli (OS, P<0.001), and neural invasion (OS, P<0.001). In the dMMR/MSI-H colorectal subgroup, colon cancer patients exhibited superior DFS compared to rectal cancer (P=0.025) and improved DFS with right colon tumors (P=0.01). Patients with MLH2/MSH6 deficiency showed a trend towards better survival, even within the subgroup receiving adjuvant chemotherapy (P=0.067), compared to MLH1/PMS2 and other deficiency disorders. Notably, patients with dMMR and/or MSI-H exhibited a shorter DFS following adjuvant therapy (P<0.001), while OS did not achieve a significant difference, potentially due to the insufficient follow-up duration. Conclusions: This study provides valuable insights into the correlation between MSI-H/dMMR status and clinical characteristics in Chinese patients with gastric and colorectal cancer after radical resection. The findings also illuminate prognostic factors impacting DFS and OS, as well as the intricate relationship between MMR/MSI status and tumor metastasis patterns. It highlights the feasibility of utilizing both MMR-IHC and MSI-PCR for patient selection and enhances our understanding of the clinical management and outcomes of patients with dMMR/MSI-H gastric and colorectal cancer.

Survival outcomes in locally advanced dMMR rectal cancer: surgery plus adjunctive treatment vs. surgery alone

Neoadjuvant Radiotherapy Improves Overall Survival for T3/4N+M0 Rectal Cancer Patients: a Population-Based Study of 20300 Patients

The Relationship Between Mismatch Repair (MMR) Proteins Status and the Response to Conventional Neoadjuvant Therapy in Colorectal Cancer (CRC).

Survival Outcomes Analysis According to Mismatch Repair Status in Locally Advanced Rectal Cancer Patients Treated with Neoadjuvant Chemoradiotherapy

Unveiling prognosis and traits of dMMR/MSI-H gastric and colorectal cancer after curative surgery: A large-scale, multi-center, retrospective study in China.

Outcomes of surgery for gastric cancer with distant metastases: a retrospective study from the SEER database.

Anti-PD-1-based immunotherapy as curative-intent treatment in dMMR/MSI-H rectal cancer: A multicentre cohort study

Immunotherapy Combined with Local Therapy in the Late-Line Treatment of Repair-Proficient (pmmr)/microsatellite Stable (MSS) Metastatic Colorectal Cancer

Patterns and prognosis of locally recurrent rectal cancer following multidisciplinary treatment.

Long-term efficacy of preoperative chemoradiotherapy combined with total mesorectal excision for locally advanced rectal cancer: an analysis of 241 patients

The prognostic and predictive value of mismatch repair status in patients with locally advanced rectal cancer following neoadjuvant therapy

Long-term survivals of immune checkpoint inhibitors as neoadjuvant and adjuvant therapy in dMMR/MSI-H colorectal and gastric cancers

Loss of Survival Advantage for Deficient Mismatch Repair in Patients with Advanced Colorectal Cancer May Be Caused by Changes in Prognostic Value of CD8+T Cell

The Results of Preoperative Chemoradiation Followed by Surgery on Rectal Cancer Patients Diagnosed MRF+ or T4b

Survival of Patients with Deficient Mismatch Repair Versus Proficient Mismatch Repair Metastatic Colorectal Cancer Receiving Curative-Intent Local Treatment of Metastases in a Nationwide Cohort

Prognostic Factors of Rectal Cancer Treated with Multimodality Therapy Based on Surgery

The Pattern and Treatment Outcomes for Rectal Cancer with Concurrent Locoregional Recurrence and Distant Metastases after Total Mesorectal Excision

Multidisciplinary team quality improves the survival outcomes of locally advanced rectal cancer patients: A post hoc analysis of the STELLAR trial

Impact of mismatch repair or microsatellite status on the prognosis and efficacy to chemotherapy in metastatic colorectal cancer patients: A bi-institutional, propensity score-matched study

Long-Term Outcomes of dMMR/MSI-H Rectal Cancer Treated With Anti–PD-1–Based Immunotherapy as Curative-Intent Treatment

Prognostic and Predictive Value of Mismatch Repair Deficiency in Gastric and Gastroesophageal Junction Adenocarcinoma Patients Receiving Neoadjuvant or Adjuvant Chemotherapy.